From the Journals
From the Journals
Ovarian cancer: Sequencing strategy identifies biomarker that could guide treatment
Novel sequencing strategy appears to be a reliable predictor of homologous recombination DNA repair deficiency.
Latest News
Lower racial disparity in melanoma diagnoses in vets than U.S. men overall, study finds
Melanoma was the fourth-most common cancer diagnosed in male VA patients.
From the Journals
New CLL meds: Improved survival rates, 1990-2018
A just-published retrospective study shows nearly 30 years of steady progress in lengthening the lives of U.S. adults with CLL and other leukemias...
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.
From the Journals
Warning on use of sotorasib after ICI in lung cancer
“We suggest avoiding starting sotorasib within 30 days from the last anti–PD-(L)1 infusion.”
From the Journals
Lack of paid sick leave is a barrier to cancer screening
For those with paid sick leave mandates, screening rates are higher.
From the Journals
Focus of new ASH VTE guidelines: Thrombophilia testing
New guidelines recommend testing for thrombophilia in patients with VTE provoked by a nonsurgical major transient risk factor or associated with...
From the Journals
Venetoclax boosts ibrutinib in high-risk CLL
Most patients in a small study reached undetectable measurable disease after taking combo therapy for high-risk CLL.
Latest News
Limit PSA screening to men with symptoms
This would reduce potential harms from overdiagnosis and overtreatment, the risk for which is high with the on-demand screening that is the...
From the Journals
Review supports continued mask-wearing in health care visits
Masks continue to lower the risk of catching the virus during medical visits.
From the Journals
Mailed HPV test kits boost cervical cancer screening
About 23% of eligible women are overdue for cervical cancer screening by at least a year.